A Pilot Study to Evaluate the Use of C1 Esterase Inhibitor (Human) in Patients With Acute Antibody-Mediated Rejection

Completed · Phase 2 · Has a placebo group

Conditions studied: Graft Rejection

In brief

The purpose of this research study is to evaluate the safety, effect, and pharmacology of C1 Esterase Inhibitor (human) in kidney transplant patients with acute Antibody-Mediated Rejection (AMR).

Key facts

Study ID

NCT01147302

Run by

Shire

People needed

18

Starts

2011-08-24

Expected to finish

2013-06-28

Last updated by the study team

2021-06-11

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• ViroPharma Investigative Site — Los Angeles, California, United States
• ViroPharma Investigative Site — Baltimore, Maryland, United States
• ViroPharma Investigative Site — Minneapolis, Minnesota, United States
• ViroPharma Investigative Site — Cincinnati, Ohio, United States
• ViroPharma Investigative Site — Heidelberg, Germany

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.